These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21917561)

  • 1. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
    Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
    J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.
    Burns CJ; Fantino E; Phillips ID; Su S; Harte MF; Bukczynska PE; Frazzetto M; Joffe M; Kruszelnicki I; Wang B; Wang Y; Wilson N; Dilley RJ; Wan SS; Charman SA; Shackleford DM; Fida R; Malcontenti-Wilson C; Wilks AF
    Mol Cancer Ther; 2009 Nov; 8(11):3036-45. PubMed ID: 19887548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cat's whiskers tea (Orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation.
    Ahamed MB; Aisha AF; Nassar ZD; Siddiqui JM; Ismail Z; Omari SM; Parish CR; Majid AM
    Nutr Cancer; 2012; 64(1):89-99. PubMed ID: 22136553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
    Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
    Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer].
    Zhou ZW; Wan DS; Wang GQ; Ren JQ; Lu ZH; Lin SX; Tang SX; Ye YL; Chen G
    Ai Zheng; 2006 Jul; 25(7):818-22. PubMed ID: 16831270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.